Telomir Pharmaceuticals, INC Form 4 insider transactions

Matthew Pratt Whalen, a Director of Telomir Pharmaceuticals, Inc., received 50,000 shares of common stock on April 16, 2026.

Edward Clouston Macpherson, a Director of Telomir Pharmaceuticals, Inc., received 50,000 shares of common stock on April 16, 2026.

Giudice Matthew Paul Del, a Director of Telomir Pharmaceuticals, Inc., received 50,000 shares of common stock on April 16, 2026.

Telomir Pharmaceuticals CEO Erez Aminov cancelled existing stock options in exchange for new grants with lower exercise prices.

Director Matthew Pratt Whalen cancelled existing stock options in exchange for new options with a lower exercise price.

Director Edward Clouston MacPherson cancelled existing stock options to receive new options with a lower exercise price.

Director Matthew Del Giudice exchanged existing stock options for new options with a lower exercise price.

CEO and Chairman Erez Aminov acquired 7,319,710 shares of Telomir Pharmaceuticals, Inc. common stock as part of the company's acquisition of TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. CEO and Chairman Erez Aminov was granted 2,000,000 non-qualified stock options and 400,000 restricted stock units (RSUs) on May 28, 2025, as reported in a recent SEC Form 4 filing.

Bay Shore Trust, a 10% owner of Telomir Pharmaceuticals, acquired 100,000 stock options at a price of $3.73 per share.

Michelle Yanez, CFO of Telomir Pharmaceuticals, reports the acquisition of incentive stock options.

Director Michael Jerman acquired 25,000 incentive stock options in Telomir Pharmaceuticals on August 27, 2024.

Director Edward Clouston MacPherson acquired 25,000 incentive stock options in Telomir Pharmaceuticals on August 27, 2024.

Erez Aminov, CEO and Chairman of Telomir Pharmaceuticals, acquired 1,960,170 incentive stock options on August 27, 2024, as part of the company's 2023 Omnibus Incentive Plan.

Matthew Paul Del Giudice, a director of Telomir Pharmaceuticals, acquired incentive stock options for 25,000 shares on August 27, 2024.

Director Matthew Whalen reports acquisition of incentive stock options in Telomir Pharmaceuticals.